By John Kennedy ( October 15, 2015, 7:34 PM EDT) -- The end payors, direct purchasers and retailers alleging Endo paid roughly $112 million to delay a generic of painkiller Opana ER had ignored parts of a recent decision in a similar antitrust multidistrict litigation they cited in fighting dismissal bids, the drugmaker argued Thursday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.